StockNews.com Upgrades Ascendis Pharma A/S (NASDAQ:ASND) to Hold

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

A number of other equities research analysts have also recently weighed in on the company. TD Cowen dropped their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Bank of America lifted their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Evercore ISI increased their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 17th. Stifel Nicolaus raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Finally, The Goldman Sachs Group upped their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Price Performance

NASDAQ ASND opened at $123.02 on Wednesday. Ascendis Pharma A/S has a 12 month low of $90.13 and a 12 month high of $161.00. The stock has a market capitalization of $7.46 billion, a P/E ratio of -15.22 and a beta of 0.66. The firm’s 50-day moving average is $133.01 and its two-hundred day moving average is $132.26.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analysts’ expectations of $94.74 million. As a group, analysts anticipate that Ascendis Pharma A/S will post -7.45 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Signaturefd LLC grew its position in Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares during the last quarter. Profund Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 3.0% in the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock valued at $398,000 after acquiring an additional 85 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 143 shares during the period. Thrivent Financial for Lutherans raised its holdings in Ascendis Pharma A/S by 0.3% during the third quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock worth $11,717,000 after purchasing an additional 228 shares in the last quarter. Finally, Avior Wealth Management LLC raised its holdings in Ascendis Pharma A/S by 3.0% during the third quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company’s stock worth $1,226,000 after purchasing an additional 240 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.